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Background
The introduction of second generation antipsychotics pro-
vided mental health professionals effective first line
agents for the treatment of schizophrenia and other psy-
choses, which cause less side effects than first generation
ones. The expanding use of these drugs is strongly corre-
lated with the development of metabolic syndrome in the
long-term, resulting in serious medical comorbidities of
psychotic patients, such as cardiovascular events.
Materials and methods
A Medline search was conducted in order to retrieve
papers concerning metabolic syndrome as a result of
antipsychotic treatment. The key words were antipsychot-
ics, schizophrenia, diabetes, hyperlipidemia, hypertriglyc-
eridemia, metabolic syndrome. A total of 110 papers was
revealed. 35 of them were used for the purpose of this
study.
Results
Second generation antipsychotics are more likely than
first generation ones to cause metabolic syndrome. The
possible mechanisms are weight gain, insulin resistance,
or a combination of these. It is possible that drugs with
increased histamine H1 receptor affinity are more likely to
cause metabolic syndrome. There are differences among
them with this respect. Olanzapine is the compound asso-
ciated with the greater incidence of weight gain, abnor-
malities in glucose-insulin homeostasis and lipid
metabolism, thus resulting in the development of meta-
bolic syndrome. Risperidone and quetiapine are less likely
to cause this side effect, while ziprasidone appears having
no impact in the development of metabolic syndrome.
There are no sufficient data for amisulpride and aripipra-
zole. Clozapine has been strongly associated with meta-
bolic adverse events, but is the most effective compound
for the treatment of refractory schizophrenia.
Discussion
The choice of a second generation agent may be influ-
enced by the potential risk for the development of meta-
bolic syndrome. Some agents should be avoided or
administrated with caution in patients being already at
risk, such as diabetic ones, or patients with high lipid
serum levels or a family history of metabolic abnormali-
ties. If such adverse effects appear during treatment, dose
reduction or switching to another agent may be appropri-
ate. Weight, lipid and glucose serum levels should be
monitored in patients receiving second generation antip-
sychotics and nutritional instructions should be given, as
well as advice for physical exercise. Clozapine remains a
special case as it is the most effective compound, but also
the most likely to cause metabolic abnormalities. Careful
management is required for patients who are at risk for
metabolic syndrome while receiving clozapine.
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